Fondaparinux Shortage: What Providers and Prescribers Need to Know in 2026

Fondaparinux Shortage: What Providers and Prescribers Need to Know in 2026

Fondaparinux (Arixtra) — the synthetic pentasaccharide selective Factor Xa inhibitor — has been experiencing intermittent supply disruptions that are impacting patient access across the United States. For providers who prescribe this anticoagulant for DVT prophylaxis, VTE treatment, or as an alternative in heparin-induced thrombocytopenia (HIT), understanding the current supply landscape is essential for clinical decision-making and patient management.

This briefing provides an overview of the current shortage status, contributing factors, prescribing implications, alternative strategies, and tools to help your patients access their medication.

Shortage Timeline and Current Status

Fondaparinux has appeared on and off drug shortage databases over the past several years. The current supply situation in early 2026 can be characterized as follows:

• Intermittent availability: Supply is inconsistent across regions, with some pharmacies having adequate stock while others report weeks-long backorders
• Strength-specific impact: The 2.5 mg and 7.5 mg prefilled syringes have been more frequently affected than the 5 mg and 10 mg strengths
• Brand discontinuation: Viatris has largely scaled back U.S. distribution of brand-name Arixtra, leaving the market dependent on generic manufacturers
• Primary generic supplier: Dr. Reddy's Laboratories remains a primary source for generic Fondaparinux in the U.S., with limited additional manufacturers

The FDA and ASHP drug shortage databases should be consulted for real-time updates, as the situation is fluid.

Prescribing Implications

The supply challenges have several clinical implications for prescribers:

DVT Prophylaxis

For post-surgical DVT prophylaxis (hip fracture, hip/knee replacement, abdominal surgery), the 2.5 mg strength is the standard dose. When this strength is unavailable, switching patients to an alternative agent is necessary rather than attempting dose modifications with available strengths.

VTE Treatment

Weight-based dosing for DVT/PE treatment (5 mg for <50 kg, 7.5 mg for 50-100 kg, 10 mg for >100 kg) means that patients may need different strengths throughout their course. If a specific strength becomes unavailable mid-treatment, transition planning becomes critical.

Heparin-Induced Thrombocytopenia

For patients with HIT, Fondaparinux represents an important therapeutic option due to its synthetic composition and lack of cross-reactivity with HIT antibodies. When Fondaparinux is unavailable for these patients, alternative non-heparin anticoagulants — such as Argatroban, Bivalirudin, or direct oral anticoagulants — should be considered in consultation with hematology.

Transition to Oral Anticoagulation

For patients being bridged to Warfarin, consider whether a direct oral anticoagulant (DOAC) such as Rivaroxaban or Apixaban might be appropriate as a single-drug strategy, eliminating the need for an injectable bridge entirely.

Current Availability Picture

Availability varies significantly by:

• Pharmacy type: Hospital pharmacies generally have better access than retail pharmacies due to purchasing contracts and Group Purchasing Organization (GPO) agreements
• Geography: Urban areas with multiple pharmacy options tend to fare better than rural areas
• Distributor relationships: Pharmacies working with multiple wholesalers have more sourcing options

Independent and specialty pharmacies may have access to secondary distribution channels that large chain pharmacies do not. Medfinder for Providers can help you direct patients to pharmacies with confirmed stock.

Cost and Access Considerations

Cost remains a significant barrier for many patients, particularly those without insurance or with high-deductible plans:

• Retail pricing: Generic Fondaparinux 2.5 mg (10 syringes) averages approximately $2,497 at retail without discounts
• Discount card pricing: Patients using GoodRx, SingleCare, or similar programs can access prices ranging from $83 to $315 for 10 syringes
• Insurance coverage: Most plans cover generic Fondaparinux, but prior authorization may be required. Step therapy protocols may require documentation that Enoxaparin was tried or is contraindicated
• Patient assistance: The Viatris Patient Assistance Program may cover eligible uninsured patients for brand Arixtra. NeedyMeds and RxAssist provide directories of additional assistance options

When cost is a factor, consider whether an oral DOAC with generic availability might be more affordable and accessible for the patient's specific indication.

Alternative Agents: Clinical Considerations

When Fondaparinux is unavailable, the following alternatives should be considered based on indication and patient factors:

For DVT Prophylaxis (Post-Surgical)

• Enoxaparin (Lovenox): First-line alternative for most patients. Generic widely available. 40 mg SC once daily for medical/abdominal surgery, 30 mg SC q12h or 40 mg SC daily for orthopedic surgery. Not appropriate for HIT patients.
• Rivaroxaban (Xarelto): FDA-approved for DVT prophylaxis after hip/knee replacement. 10 mg PO once daily. Generic now available.
• Apixaban (Eliquis): 2.5 mg PO twice daily approved for DVT prophylaxis after hip/knee replacement in many guidelines. Generic available.

For DVT/PE Treatment

• Enoxaparin: 1 mg/kg SC q12h or 1.5 mg/kg SC once daily, bridged to Warfarin
• Rivaroxaban: 15 mg PO q12h for 21 days, then 20 mg PO once daily — single-drug approach, no bridging needed
• Apixaban: 10 mg PO q12h for 7 days, then 5 mg PO q12h — single-drug approach, no bridging needed

For Heparin-Induced Thrombocytopenia

• Argatroban: IV direct thrombin inhibitor, requires continuous infusion and aPTT monitoring
• Bivalirudin (Angiomax): IV direct thrombin inhibitor, often used in PCI settings
• DOACs: Emerging evidence supports Rivaroxaban or Apixaban for stable HIT patients, though this remains an evolving area of practice

For a patient-facing guide to alternatives: Alternatives to Fondaparinux If You Can't Fill Your Prescription.

Tools and Resources for Your Practice

• Medfinder for Providers: Direct patients to pharmacies with confirmed Fondaparinux stock. Saves time for your staff and reduces patient call-backs.
• ASHP Drug Shortage Database: Monitor the latest shortage updates and manufacturer communications
• FDA Drug Shortage Database: Official shortage reports with estimated resolution timelines when available
• Discount card resources: GoodRx, SingleCare, and RxSaver can significantly reduce out-of-pocket costs for uninsured or underinsured patients

For patient-facing resources you can share: How to Find Fondaparinux in Stock Near You.

Looking Ahead

The Fondaparinux supply situation is expected to remain variable through 2026. Key developments to watch include:

• Potential entry of additional generic manufacturers, which could increase supply and reduce pricing
• Continued growth in DOAC utilization, which may reduce overall Fondaparinux demand for some indications
• Evolving guidelines on DOAC use in HIT, which could affect Fondaparinux's role in this niche

Staying informed about supply trends and having a clear transition plan for patients will help minimize treatment disruptions.

Final Thoughts

The intermittent Fondaparinux shortage requires prescribers to maintain awareness of supply conditions and have alternative strategies ready. For most indications, well-established alternatives exist. The greatest clinical concern is for HIT patients, where Fondaparinux's unique profile makes it harder to replace.

Proactive communication with patients — including setting expectations about availability, directing them to tools like Medfinder, and discussing contingency plans — will help ensure continuity of anticoagulation therapy.

For your patients' reference, share these resources:

• Fondaparinux Shortage Update: What Patients Need to Know in 2026
• How to Save Money on Fondaparinux in 2026
• How to Help Your Patients Find Fondaparinux in Stock